Early Feasibility Study of the FIRE1™ System in Heart Failure Patients (FUTURE-HF2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05763407 |
Recruitment Status :
Active, not recruiting
First Posted : March 10, 2023
Last Update Posted : March 8, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure | Device: FIRE1 System | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Early Feasibility Study of the FIRE1™ System in Heart Failure Patients (FUTURE-HF2) |
Actual Study Start Date : | June 19, 2023 |
Estimated Primary Completion Date : | May 2024 |
Estimated Study Completion Date : | February 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: FIRE1 System
FIRE1 System
|
Device: FIRE1 System
FIRE1 System |
- Primary Safety Endpoint - Procedural success [ Time Frame: 30 days ]Procedural success defined as Sensor deployment at the intended site without procedural related SAEs
- Primary Safety Endpoint - Freedom from Sensor Complications [ Time Frame: 3 months ]Freedom from Sensor complications including device migration, clinically significant fracture and/or clinically significant perforation of the Inferior Vena Cava (IVC) or symptomatic caval thrombosis
- Primary Effectiveness Endpoint - Device Performance [ Time Frame: 3 months ]Device performance defined as an assessment of the ability of the FIRE1™ System to successfully transmit collected data to a secure database
- Exploratory Safety Outcome [ Time Frame: 24 months ]Summary of all device / system related adverse events (AEs)
- Exploratory Safety Outcome [ Time Frame: 24 months ]Summary of all device / system related complications
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria
- Adults 18 years or older
-
Patients meeting diagnostic criteria for heart failure diagnosis for greater than 90 days and are on optimally tolerated medical therapy for at least 30 days, as recommended according to current AHA/ACC guidelines regardless of ejection fraction as evidenced by:
- A heart failure decompensation resulting in a hospitalisation or heart failure failure related treatment in a hospital day-care setting or unscheduled visit to a healthcare provider for administrator of an intravenous diuretic up to 12 months prior to enrolment and
- Chronic heart failure, as evidenced by a screening B-type natriuretic peptide (BNP) ≥300 pg/mL or N-terminal-pro-B type natriuretic peptide (NT-proBNP) ≥1000 pg/mL, or BNP ≥500 pg/mL or NT-proBNP ≥1,600 pg/mL for subjects presenting with atrial fibrillation at screening. For subjects treated with an angiotensin receptor neprilysin inhibitor (ARNI) in the 4 weeks prior to screening only NT-proBNP values should be considered, and
- Patients must also be on a daily oral loop diuretic dose of 40mg or greater furosemide equivalents for the 2 weeks prior to screening.
- Signed patient informed consent form
Main Exclusion Criteria:
- Significant comorbidity that, in the investigator's opinion, would results in the patient being unable to safely undergo the procedure or participate in the clinical investigation.
- Patients with an estimated Glomerular Filtration Rate (eGFR) < 25 ml/min/1.73m2
- Patients with an in vivo IVC filter, abnormal IVC or femoral venous anatomy or known congenital malformation or absence of IVC or occlusive or free-floating thrombus in the IVC.
- Patients who have severe right sided valvular disease or a right sided mechanical valve.
- Patients with a cardiac resynchronization therapy device implanted ≤ 3 months to prior to screening.
- Patients who have undergone invasive cardiac surgery in the 3 months prior to screening.
- Patients who have undergone percutaneous valve / structural heart intervention in in the 3 months prior to screening.
- Patients who have received heart transplant or a ventricular assist device or planned for advanced therapies within the next year.
- Patients with conditions associated with occlusion of the IVC, iliac or common femoral veins.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05763407
United States, New York | |
Columbia University Irving Medical Center/ New York Presbyterian Hospital | |
New York, New York, United States, 10032 | |
Rochester General Hospital | |
Rochester, New York, United States, 14621 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Ohio | |
The Ohio State University Wexner Medical Center | |
Columbus, Ohio, United States, 43210 | |
United States, Texas | |
Austin Heart Central at the Heart Hospital of Austin | |
Austin, Texas, United States, 78756 |
Responsible Party: | Foundry Innovation & Research 1, Limited (FIRE1) |
ClinicalTrials.gov Identifier: | NCT05763407 |
Other Study ID Numbers: |
TF03-CID02 |
First Posted: | March 10, 2023 Key Record Dates |
Last Update Posted: | March 8, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Cardiovascular Disease |
Heart Failure Heart Diseases Cardiovascular Diseases |